-
-
-
-
-
-
-
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
-
-
-
-
-
-
-
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
-
-
-
-
-
-
-
Esperion to Participate in Jefferies London Healthcare Conference
-
-
-
-
-
-
-
UPDATE: Jefferies Downgrades Esperion Therapeutics (ESPR) to Hold
-
-
-
-
-
-
-
Esperion to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR): Solid set-up into '18 - Jefferies
-
-
-
-
-
-
-
Esperion to Present at the Jefferies 2017 Global Healthcare Conference
-
72,201 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

